What is [68Ga]Ga-Sa-DABI-4 studying for cancer patients?

[68Ga]Ga-Sa-DABI-4 is being studied to see if it can safely and effectively image the expression of the STING protein in tumors. This helps researchers understand the tumor environment better and may guide future treatments. The study is sponsored by the First Affiliated Hospital of Chongqing Medical University.

Who may be eligible for this cancer clinical trial?

Adults aged 18 or older with suspected, newly diagnosed, or previous malignant disease may be eligible. This study is open to all genders. People who are pregnant or have non-malignant diseases are not eligible. Please review eligibility criteria for more details.

Is there any cost to participate in this cancer clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. Travel costs and other personal expenses may vary and are not guaranteed to be covered.

Actively Recruiting

Early Phase 1

Age: 18Years +

All Genders

Healthy Volunteers

ID06419361

68GaGa-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Led by First Affiliated Hospital of Chongqing Medical University · Updated on 2025-06-04

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying the stimulator of interferon gene STING protein, which plays an important role in the immune systems ability to detect tumors. This trial focuses on evaluating a new imaging agent called 68GaGa-Sa-DABI-4, designed to noninvasively detect STING expression in the tumor environment using positron emission tomography PET. The study aims to assess the safety, distribution in the body, and potential usefulness of this imaging agent for cancer patients. Participants will receive one intravenous injection of the investigational drug 68GaGa-Sa-DABI-4 during the study. This single administration is followed by PET imaging to monitor how the agent interacts with the tumor. The study is conducted in an early phase 1 design, focusing on initial safety and diagnostic capabilities. During the trial, participants will undergo PET scans to evaluate the diagnostic effectiveness of the imaging agent within 15 days after injection. Researchers will monitor safety and how the drug distributes throughout the body. The study includes patients suspected of having or newly diagnosed with malignant diseases. Participation involves a single dosing and imaging session, with safety and diagnostic data collected during this period.

CONDITIONS

Brief Title

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Who Can Participate

Age: 18Years +

All Genders

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

At least 18 years of age
Signed informed consent
Patients with suspected, newly diagnosed, or previous malignant disease

You will not qualify if you...

Patients with non-malignant disease
Patients who are pregnant
Inability or unwillingness to provide written informed consent
Known or expected hypersensitivity to [68Ga]Ga-Sa-DABI-4 or its components
Any serious medical condition or circumstance that may interfere with study procedures or evaluations

Research Team

Xiaoyang Zhang, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here